Table 2.
ts-AML population disease characteristics and outcomes
| Variable | Age <60 y (N = 51) | Age ≥60 y (N = 203) | P |
|---|---|---|---|
| Median (range) or no./proportion (%) | |||
| Age, y | 52 (15-59) | 71 (60-92) | — |
| WBCs, ×109/L | 3 (1-78) | 4 (0-195) | .71 |
| Platelets, ×109/L | 26 (1-227) | 31 (2-936) | .22 |
| PB blasts, % | 21 (0-99) | 14 (0-98) | .68 |
| LDH, IU/L | 779 (287-22 798) | 688 (13-8564) | .46 |
| Total bilirubin, mg/dL | 1 (0-2) | 1 (0-2) | .62 |
| Creatinine, mg/dL | 1 (0-1) | 1 (0-3) | .002 |
| BM blasts, % | 29 (9-93) | 33 (6-94) | .62 |
| Number of prior therapies | 1 (1-5) | 1 (1-6) | .14 |
| Prior AHD, no. (%) | |||
| MDS | 43 (84) | 186 (92) | .002 |
| MPN | 5 (10) | 16 (8) | |
| AA | 3 (6) | 1 (1) | |
| Prior AHD therapy, no. (%) | |||
| Hypomethylating agent | 28 (55) | 153 (75) | .002 |
| Thalidomide/lenalidomide/cyclosporine | 8 (16) | 25 (12) | |
| Ruxolitinib/hydroxyurea | 5 (10) | 13 (18) | |
| Other chemotherapy/immunomodulator therapy* | 10 (19) | 10 (5) | |
| Karyotype | |||
| Adverse | 30/51 (58) | 79/179 (39) | .10 |
| Diploid/intermediate | 20/51 (40) | 98/179 (51) | |
| Favorable | 1/51 (2) | 2/179 (1) | |
| 5q/7q abnormality | 23/51 (45) | 66/179 (37) | .28 |
| Complex | 21/51 (41) | 57/179 (32) | .14 |
| 3q abnormality | 8/51 (16) | 22/179 (12) | .53 |
| Mutations* | |||
| FLT3-ITD | 3/41 (7) | 21/179 (12) | .41 |
| FLT3D835 | 1/41 (3) | 8/179 (4.5) | .55 |
| NPM1 | 3/26 (4) | 14/131 (11) | .89 |
| RAS | 8/38 (21) | 34/176 (19) | .81 |
| TP53 | 1/10 (10) | 8/54 (5) | .68 |
| Regimens | |||
| N, evaluable | 47/51 | 179/203 | — |
| High intensity, no. (%) | 31 (66) | 31 (17) | .001 |
| Medium intensity, no. (%) | 7 (15) | 11 (6) | |
| Low intensity, no. (%) | 9 (19) | 137 (77) | |
*
Patients treated with stimulating agents such as growth factor supplements, recombinant erythropoietin and analogs, and danazol alone not considered to have ts-AML.